Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $192.1 million.

  • Dexcom's Free Cash Flow rose 865.38% to $192.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 7079.44%. This contributed to the annual value of $1.1 billion for FY2025, which is 7079.44% up from last year.
  • Latest data reveals that Dexcom reported Free Cash Flow of $192.1 million as of Q4 2025, which was up 865.38% from $579.4 million recorded in Q3 2025.
  • Over the past 5 years, Dexcom's Free Cash Flow peaked at $579.4 million during Q3 2025, and registered a low of -$71.9 million during Q1 2021.
  • Its 5-year average for Free Cash Flow is $128.9 million, with a median of $114.0 million in 2023.
  • In the last 5 years, Dexcom's Free Cash Flow tumbled by 14129.3% in 2021 and then surged by 55617.21% in 2025.
  • Dexcom's Free Cash Flow (Quarter) stood at $25.6 million in 2021, then soared by 169.53% to $69.0 million in 2022, then grew by 17.54% to $81.1 million in 2023, then soared by 118.0% to $176.8 million in 2024, then grew by 8.65% to $192.1 million in 2025.
  • Its Free Cash Flow was $192.1 million in Q4 2025, compared to $579.4 million in Q3 2025 and $208.9 million in Q2 2025.